Alendronate for Low BMD in HIV-infected Youth

Phase 2, randomised, double-blind trial of alendronate in low bone mineral density (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD and Percentage of Participants Developing New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or… at 48 weeks. Started Nov 2009; status: completed.